Latest Breaking News On - கவுஸ் மருந்துகள் - Page 5 : comparemela.com

Markets Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) today and set a price target of $21.00. The company’s shares closed last Friday at $12.35. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 15.5% and a 43.1% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neoleukin Therapeutics with a $21.50 average price target. The company has a one-year high of $18.13 and a one-year low of $9.63. Currently, Neoleukin Therapeutics has an average volume of 208.7K.

Daniel adriano silvaCarl walkeyMara goldsteinUmut ulgeIovance biotherapeuticsCorvus pharmaceuticalsNeoleukin therapeutics incMizuho securitiesNeoleukin therapeuticsResearch reportAdaptimmune therapeuticsModerate buyகார்ல் வால்கிமாரா கோல்ட்ஸ்டைன்கவுஸ் மருந்துகள்மீஜுஹோ பத்திரங்கள்